Core Insights - Izotropic Corporation is highlighted in an editorial by NetworkNewsWire, emphasizing its role in the AI-driven imaging sector targeting the breast cancer market [1][2]. Industry Overview - The healthcare sector is experiencing significant transformation due to artificial intelligence, particularly in medical imaging, which is crucial for breast cancer detection [2]. - Breast cancer is the most commonly diagnosed cancer among women globally, with over 2.3 million diagnoses and approximately 670,000 deaths reported by the World Health Organization in 2022 [2]. - In the United States, the American Cancer Society estimates 316,950 new invasive breast cancer cases for the current year [2]. Company Highlights - Izotropic Corporation is developing the IzoView Breast CT Imaging System, a specialized 3D imaging solution aimed at improving cancer detection accuracy, especially in women with dense breast tissue [3]. - The company focuses on innovative technologies and imaging products for more accurate screening, diagnosis, and treatment of breast cancers [4].

Core Insights - Izotropic Corporation is highlighted in an editorial by NetworkNewsWire, emphasizing its role in the AI-driven imaging sector targeting the breast cancer market [1][2] Industry Overview - The healthcare sector is experiencing significant transformation due to artificial intelligence, particularly in medical imaging, which is crucial for breast cancer detection [2] - Breast cancer is the most commonly diagnosed cancer among women globally, with over 2.3 million diagnoses and approximately 670,000 deaths reported by the WHO in 2022 [2] - In the U.S., the American Cancer Society estimates 316,950 new invasive breast cancer cases for the current year [2] Company Highlights - Izotropic Corporation is developing the IzoView Breast CT Imaging System, a 3D imaging solution designed to improve cancer detection accuracy, especially in women with dense breast tissue [3] - The company focuses on innovative technologies and imaging products for more accurate screening, diagnosis, and treatment of breast cancers [4]

Core Insights - Izotropic Corporation is highlighted in an editorial by NetworkNewsWire, emphasizing its role in the growing market for next-generation 3D AI-imaging technologies, particularly in breast cancer diagnostics [1][2]. Industry Overview - The global market for breast cancer diagnostics is projected to reach $9 billion, driven by the urgent need for earlier and more accurate detection methods [2][3]. - Breast cancer remains one of the most prevalent cancers among women, with over 2.3 million diagnoses and approximately 670,000 deaths globally in 2022, according to the World Health Organization [2]. Company Highlights - Izotropic Corporation is focused on commercializing innovative imaging technologies, specifically the IzoView Breast CT Imaging System, which aims to enhance detection accuracy for women with dense breast tissue [3][4]. - The company is positioned to capitalize on the increasing demand for advanced diagnostic imaging solutions in the context of breast cancer detection [3].

Core Insights - Izotropic Corporation highlights the limitations of current breast cancer imaging tools and the commercial opportunity for its IzoView Breast CT Imaging System during Breast Cancer Awareness Month [1][11] Industry Overview - Breast cancer is the most commonly diagnosed cancer among women globally, with over 2.3 million new cases annually. In the U.S., over 315,000 cases are expected in 2025, accounting for nearly one in three new cancer diagnoses in women [2] - The global breast imaging technology market is projected to grow from USD $5.4 billion in 2024 to USD $8.69 billion by 2030, reflecting a CAGR of 8.25% [2] Unmet Needs - There is a significant need for high-resolution, true 3D imaging modalities, particularly for women with dense breast tissue, which affects about 50% of women and reduces the effectiveness of traditional screening methods [3] - Current screening methods, including mammography and digital breast tomosynthesis (DBT), miss approximately 20% of breast cancers at the time of screening, with 10-12% returning false negatives [3][6] - The U.S. incurs an estimated USD $8 billion annually in follow-up imaging and diagnostic procedures due to false positives and missed cancers [3] Regulatory Landscape - In 2024, the FDA mandated that U.S. screening facilities inform women about their breast density alongside mammography results, with some states requiring recommendations for supplemental screening options [4] - The U.S. Preventive Services Task Force has called for more research on additional screening methods for women with dense breasts [5] Limitations of Current Modalities - Compression-based mammography and DBT are the primary tools but have decreased sensitivity in women with dense breast tissue, leading to missed cancers [6] - Ultrasound, while used as a supplemental tool, has high false-positive rates and is operator-dependent, complicating the workflow [7] - Breast MRI, the current gold standard for 3D imaging, is costly and time-consuming, typically reserved for high-risk patients due to high false positive rates [8] IzoView Breast CT Solution - The IzoView Breast CT Imaging System is designed for breast cancer screening in asymptomatic women with dense breast tissue, performing exams without breast compression and acquiring approximately 500 high-resolution images in about 10 seconds [9][10] - Research indicates that IzoView's technology offers superior visibility of malignant masses compared to mammography and DBT, with spatial resolution approximately 100 times greater than MRI [9] - The target sales price for the IzoView device is USD $500,000, aimed at facilitating adoption across various imaging environments [10] Conclusion - The ongoing challenges in breast cancer screening, particularly for women with dense breast tissue, underscore the need for innovative imaging solutions like the IzoView Breast CT, which aims to enhance early detection and improve patient care [11][12]

VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, is pleased to announce the publication of a new feature article on BreastCT.com titled “AI Is Reshaping Breast Imaging, and IzoView Was Built f ...

Core Insights - Izotropic Corporation is advancing its commercialization strategy for the IzoView Breast CT Imaging System, emphasizing its role in AI-integrated breast imaging [1][2] - The publication on BreastCT.com highlights the limitations of legacy imaging systems and positions IzoView as a future-ready solution for intelligent imaging [2][6] Company Overview - Izotropic Corporation focuses on innovative medical devices for breast cancer screening, diagnosis, and treatment [1] - The company is enhancing awareness of its flagship product, the IzoView Breast CT Imaging System, through educational content [1][2] Industry Context - There is a growing global demand for advanced breast cancer screening solutions, particularly for patients with dense breast tissue [2][6] - Traditional imaging systems are often inadequate for AI integration, limiting their effectiveness in dense tissue scenarios [6] Product Features - IzoView is designed specifically for AI-driven imaging, featuring a proprietary reconstruction algorithm and true 3D hardware [6] - The system provides high-quality images in just 10 seconds, with a target price of USD $500,000, making it a scalable and future-ready platform [6]

Core Insights - Izotropic Corporation has integrated a patent-pending radiation dose personalization feature into its IzoView Breast CT Imaging System, making it the first breast CT system to offer real-time customized radiation dosing [1][2] - The global breast imaging device market is projected to grow from USD $5.4 billion in 2024 to USD $8.69 billion by 2030, driven by trends in personalized medicine and rising breast cancer incidence [4] Company Developments - The optical pre-scan system captures a radiation-free image to calculate a personalized radiation dose based on each patient's breast size, enhancing operational efficiency and patient comfort [2][3] - IzoView is advancing through the U.S. FDA's Pre-Market Approval process and is preparing to initiate a pivotal clinical study in the U.S. while also aiming for a European CE Mark submission [5] Market Trends - The introduction of personalized radiation dosing aligns with a broader market shift towards personalized medicine, adapting screening protocols to individual risk factors [4] - The growth of the breast imaging market is supported by expanded reimbursement for supplemental screening in women with dense breast tissue and the adoption of technologies that enable individualized imaging protocols [4]

Core Insights - Izotropic Corporation has integrated a patent-pending radiation dose personalization feature into its IzoView Breast CT Imaging System, making it the first system to offer real-time customized radiation dosing tailored to individual patient needs [1][2] - The global breast imaging device market is projected to grow from USD $5.4 billion in 2024 to USD $8.69 billion by 2030, driven by trends in personalized medicine and increasing breast cancer incidence [4] Company Developments - The optical pre-scan technology captures a radiation-free image of the breast to calculate a personalized radiation dose based on breast size, enhancing operational efficiency and patient comfort [2][3] - IzoView is advancing through the U.S. FDA's Pre-Market Approval process and is preparing to initiate a pivotal clinical study in the U.S. to support its market entry [5] Market Trends - The introduction of personalized radiation dosing aligns with a broader market shift towards personalized medicine, adapting screening protocols to individual risk factors such as breast density and family history [4] - The growth of the breast imaging market is supported by expanded reimbursement for supplemental screening and the adoption of technologies that enable individualized imaging protocols [4]

Core Insights - Izotropic Corporation has launched a new FAQ page on its corporate website to enhance transparency and provide essential information about its flagship product, the IzoView Breast CT Imaging System [1][2]. Company Overview - Izotropic Corporation is focused on commercializing innovative technologies and imaging products aimed at improving the screening, diagnosis, and treatment of breast cancers [1]. - The company holds exclusive global rights to commercialize breast CT technology developed at the University of California, Davis [3]. Product Information - The FAQ page includes comparisons of IzoView with traditional imaging methods such as mammography, tomosynthesis, ultrasound, and MRI [3]. - It highlights the importance of breast density in cancer detection and describes IzoView's non-compressive, patient-centered imaging workflow [3]. Strategic Communication - The FAQ resource is designed as an informational tool for various stakeholders, including shareholders, analysts, healthcare professionals, and breast cancer advocates [3]. - The page is optimized for search engine indexing and AI platforms to improve discoverability across investor, clinical, and media channels [4]. Market Positioning - As interest in next-generation imaging solutions for dense breast tissue increases, breast CT is emerging as a promising modality [5]. - IzoView is engineered for high-resolution, 360-degree, true 3D imaging, positioning the company favorably in the breast imaging market [5].

Core Insights - The BioMedWire Podcast features an interview with Robert Thast, CEO of Izotropic Corp, focusing on the company's innovative technologies for breast cancer screening and diagnosis [2][3][4] Company Overview - Izotropic Corp is a medical device company that is commercializing the IzoView Breast CT Imaging System, which aims to improve early cancer detection by identifying cancers as small as 2 millimeters, compared to the current standard of care that averages 11 millimeters [3][4] Technology and Innovation - The company has developed unique AI capabilities that are expected to gain acceptance in the market, potentially making Izotropic a target for acquisition by larger firms [5] - Izotropic's intellectual property strategy includes a portfolio of patents and trade secrets to protect its innovations in the imaging space [5] Market Strategy - The commercialization strategy involves a phased rollout of the IzoView system, starting in Europe and then expanding to the U.S., targeting hospitals, medical facilities, and imaging clinics [6] - The combined U.S. and European markets represent nearly 50% of the global market for breast imaging devices [6] Future Outlook - Securing FDA approval is seen as a critical milestone that would open up significant market opportunities for Izotropic [6]